PTK2B

Protein-tyrosine kinase 2-beta

59,923 patent compounds predicted against PTK2B, 45,072 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21346	0.47	6/20
SCHEMBL20041	0.44	6/20
SCHEMBL19831	0.38	6/20
SCHEMBL147422	0.66	5/20
SCHEMBL108541	0.44	5/20
SCHEMBL146734	0.67	4/20
SCHEMBL144651	0.67	4/20
SCHEMBL146677	0.67	4/20
SCHEMBL144378	0.66	4/20
SCHEMBL142020	0.65	4/20
SCHEMBL147132	0.64	4/20
SCHEMBL142951	0.62	4/20
SCHEMBL147730	0.61	4/20
SCHEMBL147715	0.61	4/20
SCHEMBL143818	0.61	4/20
SCHEMBL144979	0.56	4/20
SCHEMBL19806	0.36	4/20
SCHEMBL93711	1.00	3/20
SCHEMBL93713	1.00	3/20
SCHEMBL147331	0.91	3/20

Germline variants in PTK2B on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PTK2B gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PTK2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Platelet Rich Plasma in Treatment of Melasma	PHASE3	UNKNOWN
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Protein Tyrosine Kinases (PTK) in Multiple Myeloma	PHASE2	COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients	PHASE2	ENROLLING_BY_INVITATION
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP	PHASE1/PHASE2	COMPLETED
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma	PHASE2	COMPLETED
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma	PHASE1/PHASE2	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)	PHASE1	ACTIVE_NOT_RECRUITING
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration	PHASE1	COMPLETED
The Clinical Application of 68Ga Labeled ssDNA Aptamer Sgc8 in Healthy Volunteers and Colorectal Patients	EARLY_PHASE1	UNKNOWN
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTK2B binder may also engage these)

Protein	Name	Similarity
P70600	—	1.000	P70600 →
Q9QVP9	—	1.000	Q9QVP9 →
PTK2	Focal adhesion kinase 1	0.996	landscape →
O35346	—	0.995	O35346 →
Q8BX57	—	0.995	Q8BX57 →
P34152	—	0.994	P34152 →
Q60629	—	0.993	Q60629 →
P25799	—	0.993	P25799 →
Q8N9S9	—	0.993	Q8N9S9 →
O12990	—	0.993	O12990 →
Q86YR7	—	0.992	Q86YR7 →
O15068	—	0.992	O15068 →
Q63406	—	0.992	Q63406 →
NFKB1	Nuclear factor NF-kappa-B p105 subunit	0.992	landscape →
F8VPU2	—	0.992	F8VPU2 →
Q00944	—	0.992	Q00944 →
Q9Y4G8	—	0.992	Q9Y4G8 →
INPP5B	Type II inositol 1,4,5-trisphosphate 5-phosphatase	0.992	landscape →
Q64096	—	0.992	Q64096 →
Q95YD4	—	0.992	Q95YD4 →
Q9VZI3	—	0.992	Q9VZI3 →
P10911	—	0.992	P10911 →
Q9H1H9	—	0.992	Q9H1H9 →
O94887	—	0.991	O94887 →
F1M386	—	0.991	F1M386 →
Q60695	—	0.991	Q60695 →
Q2HJE1	—	0.991	Q2HJE1 →
O43150	—	0.991	O43150 →
Q99KY4	—	0.991	Q99KY4 →
P10686	—	0.991	P10686 →